ARVN — Arvinas, Inc.

Summary of Arvinas Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $15.6 million for Q1 2026, a significant decrease from $188.8 million in Q1 2025, primarily due to reduced revenue from the vepdegestrant collaboration with Pfizer.
• Expenses:
  • General and administrative expenses decreased to $19.1 million from $26.6 million year-over-year.
  • Research and development expenses were $60.3 million, down from $90.8 million, attributed to cost reduction programs.
• Cash Position: $614.9 million in cash and equivalents at the end of Q1 2026, down from $685.4 million at the end of 2025, with a cash runway projected into the second half of 2028.

2. Strategic Updates and Business Highlights

• FDA Approval: Vepdegestrant (now VEPPANU) received FDA approval for treating ESR1-mutant, ER+/HER2- advanced breast cancer, marking it as the first heterobifunctional PROTAC degrader approved.
• Partnership: Arvinas entered a global licensing agreement with Rigel Pharmaceuticals for VEPPANU, allowing Rigel to manage commercialization while Arvinas focuses on its pipeline.
• Pipeline Development:
  • Four Phase 1 clinical programs are ongoing, including ARV-102 for neurodegenerative diseases, ARV-806 for KRAS G12D cancers, ARV-393 for lymphomas, and ARV-027 for spinal and bulbar muscular atrophy.
  • Positive Phase 1 data for ARV-102 showed significant reductions in LRRK2 levels in Parkinson's disease patients.
  • ARV-806 is advancing rapidly, with initial data expected later in 2026.

3. Forward Guidance and Outlook

• Clinical Trials: Anticipate starting the Phase 1b trial for ARV-102 in PSP by the end of 2026, pending additional data requested by the FDA.
• Data Releases: Expect to share initial clinical data for ARV-806 and ARV-393 later in 2026.
• Cash Utilization: The company plans to use its cash reserves to fund ongoing clinical programs and maintain a disciplined approach to capital allocation.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: The substantial drop in revenue compared to the previous year raises concerns about the sustainability of income sources post-licensing agreements.
• Clinical Holds: ARV-102 is currently on hold in the U.S. due to FDA requests for additional data, which could delay the trial timeline.
• Competitive Landscape: The oncology space, particularly for KRAS-targeted therapies, is highly competitive, with multiple players developing similar therapies, which may impact market share and pricing.

5. Notable Q&A Insights

• Rigel Partnership Economics: Arvinas and Pfizer will split revenues from VEPPANU equally, with Rigel responsible for global commercialization.
• Clinical Trial Design: The decision to explore two dose levels in the ARV-806 Phase 2 trial is aimed at optimizing dosing and satisfying regulatory requirements.
• Patient Population for KRAS Programs: The focus on PDAC for the G12D degrader is driven by unmet medical needs and the potential for improved efficacy over existing treatments.
• PSP vs. Parkinson's Disease: Insights on LRRK2 levels suggest that reductions seen in Parkinson's patients may also apply to PSP, supporting the rationale for pursuing both indications.

This summary encapsulates the key points from Arvinas' Q1 2026 earnings call, providing a balanced view of the company's performance, strategic direction, and potential challenges ahead.